Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment.
Wei X, Yue L, Zhao B, Jiang N, Lei H, Zhai X.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2024.116785 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för telacebec. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
23 träffarExploring Scaffold Hopping for Novel 2-(Quinolin-4-yloxy)acetamides with Enhanced Antimycobacterial Activity.
Borsoi AF, Silva Ramos A, Sperotto N, Abbadi BL, Souza Macchi Hopf F, da Silva Dadda A, Scheibler Rambo R, Neves Muniz M, Delgado Paz J, Silveira Grams E, Fries da Silva F, Pissinate K, Galina L, Calle González L, Silva Duarte L, Alberton Perelló M, de Matos Czeczot A, Bizarro CV, Basso LA, Machado P.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.3c00570Cytochrome <i>bd</i> oxidase: an emerging anti-tubercular drug target.
Saha P, Das S, Indurthi HK, Kumar R, Roy A, Kalia NP, Sharma DK.
RSC Med Chem · review-article; review; journal article · DOI 10.1039/d3md00587aTargeting mycobacterial membranes and membrane proteins: Progress and limitations.
Kumar G, Kapoor S.
Bioorg Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.bmc.2023.117212Discovery of 1-hydroxy-2-methylquinolin-4(1H)-one derivatives as new cytochrome bd oxidase inhibitors for tuberculosis therapy.
Zhou Y, Shao M, Wang W, Cheung CY, Wu Y, Yu H, Hu X, Cook GM, Gong H, Lu X.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2022.114896Design, synthesis and biological evaluation of (Quinazoline 4-yloxy)acetamide and (4-oxoquinazoline-3(4H)-yl)acetamide derivatives as inhibitors of Mycobacterium tuberculosis bd oxidase.
Kumar A, Kumari N, Bhattacherjee S, Venugopal U, Parwez S, Siddiqi MI, Krishnan MY, Panda G.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2022.114639Tuberculosis Drug Discovery: Challenges and New Horizons.
Fernandes GFS, Thompson AM, Castagnolo D, Denny WA, Dos Santos JL.
J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.2c00227Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Perveen S, Kumari D, Singh K, Sharma R.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2021.114066Hydride-induced Meisenheimer complex formation reflects activity of nitro aromatic anti-tuberculosis compounds.
Liu R, Markley L, Miller PA, Franzblau S, Shetye G, Ma R, Savková K, Mikušová K, Lee BS, Pethe K, Moraski GC, Miller MJ.
RSC Med Chem · research-article; journal article · DOI 10.1039/d0md00390eSmall organic molecules targeting the energy metabolism of Mycobacterium tuberculosis.
Urban M, Šlachtová V, Brulíková L.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2020.113139Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents.
Wang A, Lv K, Li L, Liu H, Tao Z, Wang B, Liu M, Ma C, Ma X, Han B, Wang A, Lu Y.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.06.038Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties.
Wang A, Wang H, Geng Y, Fu L, Gu J, Wang B, Lv K, Liu M, Tao Z, Ma C, Lu Y.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2019.01.022Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.
Wang H, Wang A, Gu J, Fu L, Lv K, Ma C, Tao Z, Wang B, Liu M, Guo H, Lu Y.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2018.12.071Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.
Cleghorn LAT, Ray PC, Odingo J, Kumar A, Wescott H, Korkegian A, Masquelin T, Lopez Moure A, Wilson C, Davis S, Huggett M, Turner P, Smith A, Epemolu O, Zuccotto F, Riley J, Scullion P, Shishikura Y, Ferguson L, Rullas J, Guijarro L, Read KD, Green SR, Hipskind P, Parish T, Wyatt PG.
J Med Chem · research-article; journal article · DOI 10.1021/acs.jmedchem.8b00172Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.
Campaniço A, Moreira R, Lopes F.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2018.03.020Drug development against tuberculosis: Impact of alkaloids.
Mishra SK, Tripathi G, Kishore N, Singh RK, Singh A, Tiwari VK.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2017.06.005Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents.
Kang S, Kim YM, Jeon H, Park S, Seo MJ, Lee S, Park D, Nam J, Lee S, Nam K, Kim S, Kim J.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2017.05.021Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis.
Lu X, Tang J, Liu Z, Li M, Zhang T, Zhang X, Ding K.
Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2016.11.003Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents.
Tang J, Wang B, Wu T, Wan J, Tu Z, Njire M, Wan B, Franzblauc SG, Zhang T, Lu X, Ding K.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.5b00176Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore.
Salunke SB, Azad AK, Kapuriya NP, Balada-Llasat JM, Pancholi P, Schlesinger LS, Chen CS.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2015.03.041Synthesis, molecular docking and anti-mycobacterial evaluation of new imidazo[1,2-a]pyridine-2-carboxamide derivatives.
Jose G, Suresha Kumara TH, Nagendrappa G, Sowmya HB, Sriram D, Yogeeswari P, Sridevi JP, Guru Row TN, Hosamani AA, Sujan Ganapathy PS, Chandrika N, Narendra LV.
Eur J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejmech.2014.10.079SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
Poce G, Cocozza M, Consalvi S, Biava M.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2014.08.066Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.
Kang S, Kim RY, Seo MJ, Lee S, Kim YM, Seo M, Seo JJ, Ko Y, Choi I, Jang J, Nam J, Park S, Kang H, Kim HJ, Kim J, Ahn S, Pethe K, Nam K, No Z, Kim J.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm5003606